Summary
KZR Chart
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages
Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) has earned a consensus recommendation of "Reduce" from the six analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1-year price objective among
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kezar Life Sciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 308 | $2,285 | $2,285 | - | - |
| PLC Peapod Lane Capital LLC Peapod Lane Capital LLC | 126,692 | $820,144.53 | $924,520 | $104,375.47 | 12.73% |
| GLF Groupe La Francaise Groupe La Francaise | 80,400 | $596,568 | $596,568 | - | - |
Kezar Life Sciences, Inc. (KZR) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Kezar Life Sciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher J. Kirk CEO | NASDAQ (CM) Exchange | 49372L100 CUSIP |
| US Country | 55 Employees | - Last Dividend | 30 Oct 2024 Last Split | 21 Jun 2018 IPO Date |
Overview
Kezar Life Sciences, Inc. is a clinical-stage biotechnology firm actively engaged in the innovation and development of small molecule therapeutics. Founded in 2015 and located in South San Francisco, California, the company focuses its research on addressing the unmet medical needs of patients suffering from immune-mediated diseases and cancer. By harnessing its expertise in novel therapeutic development, Kezar Life Sciences aims to improve the quality of life for patients across the United States through groundbreaking medical advancements.
Products and Services
-
Zetomipzomib (KZR-616)
As the flagship product candidate of Kezar Life Sciences, Zetomipzomib represents a revolutionary approach in treating autoimmune diseases. This selective immunoproteasome inhibitor is undergoing rigorous clinical trials across various stages and indications. For patients battling lupus nephritis, dermatomyositis, and polymyositis, Zetomipzomib is in Phase 2b clinical trials. Additionally, it is in Phase 1b clinical trials for those suffering from systemic lupus erythematosus and has successfully completed Phase 2a clinical trials for lupus nephritis. This targeted treatment aims to offer a new beacon of hope for individuals facing these challenging conditions.
-
KZR-261
Kezar Life Sciences’ preclinical developments include KZR-261, a pioneering product that positions itself as a first-in-class protein secretion inhibitor. This novel compound is designed to combat tumors that have developed resistance to conventional chemotherapy treatments. By targeting the protein secretion pathways crucial for tumor growth and survival, KZR-261 has the potential to redefine cancer treatment paradigms and offer new hope to patients with hard-to-treat cancers.
